Search Results

Viewing Page 1 of 2 | Showing results 1 - 10 of 14

(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Daniela Bota
Open

(CIRB) Molecular Analysis for Therapy Choice (MATCH)

Daniela Bota
Open

A Phase 1 study of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors

UCI Health is conducting a Phase 1 clinical trial of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell...
Viola W. Zhu, MD
Viola W. Zhu, MD
Open